Elite Health Systems Inc. has announced that its subsidiary, Elite Health Plan, Inc., has received conditional approval from the Centers for Medicare and Medicaid Services $(CMS)$ for its Contract Year 2026 Medicare Advantage/Medicare - Prescription Drug (MA-Only/MA-PD) application. This marks a significant step for Elite Health Plan, allowing them to advance in the CMS regulatory process. However, final approval is contingent upon CMS's acceptance of Elite Health Plan's bid and formulary, as well as the completion of necessary pre-implementation activities, including system and data testing. The bid submission was conducted in partnership with Wakely Consulting Group. The process remains complex, and there is no assurance of ultimate approval or license maintenance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.